fda import alert green list glp-1 semaglutide tirzepatide 2025 Compounded & 2025: Safe Use Guide September 8, 2025: FDA launches

From diabetes to diverse domains: the multifaceted roles of GLP-1 receptor agonists

Here is what the verification process looks like

Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved

These adverse reactions may be precursors to more serious side effects like stomach paralysis (gastroparesis) and intestinal blockages

In an interview with the Associated Press , 38-year-old Danielle Griffin said that although she was able to get a prescription for Novo Nordisks weight loss shot Wegovy and even got it covered by her insurance, which is still often a struggle the medication just didnt work for her